Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Transfusion    symbols : BLUE    save search
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
BLUE | $0.9274 -4.45% -4.66% 8.1M twitter stocktwits trandingview |
Health Technology
 | | O: 5.7% H: 0.44% C: -6.81%
fda blood transfusion application gene therapy therapy license cel
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.